Can a blood test reveal why atrial fibrillation returns after cryoablation?

NCT ID NCT05170607

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study looks at blood samples from 120 people with atrial fibrillation who have had a procedure called cryoablation to restore normal heart rhythm. The goal is to find specific proteins in the blood that might indicate whether the irregular heartbeat is likely to come back due to triggers outside the pulmonary veins. By identifying these biomarkers, doctors may eventually be able to personalize treatment and improve long-term outcomes for people with atrial fibrillation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Proteomic analysis by antibody microarrays (a diagnostic test measuring blood proteins)
What this could lead to
If specific proteins are found, doctors might better predict which atrial fibrillation patients will need additional treatment beyond standard cryoablation.
What could go wrong
This is an early exploratory study focused on finding biomarkers, not testing a treatment. The identified proteins may not prove reliable in larger, more diverse patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2021

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients 18-85 years old with s paroxismal or persistant atrial fibrillation and prior interventional treatment

Ages

18 to 85 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: • Patient with paroxysmal/persistent atrial fibrillation who underwent interventional treatment Exclusion Criteria: * permanent AF * contraindications to oral anticoagulation or heparin * chronic kidney disease requiring dialysis * untreated hypo- or hyperthyroidism * breast feeding * pregnancy * chronic kidney disease requiring dialysis * decompensated heart failure * stroke within the last 3 months * myocardial infarction within the last 3 months * Percutaneous coronary intervention or Coronary Artery Bypass Grafting within the last 3 months * active myocarditis * artificial valve replacement surgery * severe mitral or aortic stenosis * coronary artery disease requiring revascularization * heart transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Research Center for Preventive Medicine

    Moscow, 101990, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.